Research programme: TNFR1 blockers - Inflamalps
Latest Information Update: 02 Aug 2016
At a glance
- Originator Inflamalps
- Class Venoms
- Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis; Skin disorders
Most Recent Events
- 02 Aug 2016 Preclinical trials in Atopic dermatitis in Switzerland (Topical)
- 02 Aug 2016 Preclinical trials in Skin disorders in Switzerland (Topical)